MASH drugs have reached a meaningful tipping point for patients and investors.
$MDGL already topping $400 million in annualized sales.
$AKRO reversing cirrhosis in F4 patients + $ETNB following
...
MASH drugs have reached a meaningful tipping point for patients and investors.
$MDGL already topping $400 million in annualized sales.
$AKRO reversing cirrhosis in F4 patients + $ETNB following
...
$MDGL 's Rezdiffra is prescribed mostly for patients with early and moderate MASH.
$ETNB is developing a drug similar to $AKRO. Stock up 66% pre market.
www.statnews.com/2025/01/27/a...
$MDGL 's Rezdiffra is prescribed mostly for patients with early and moderate MASH.
$ETNB is developing a drug similar to $AKRO. Stock up 66% pre market.
www.statnews.com/2025/01/27/a...
www.youtube.com/watch?v=etNb...
www.youtube.com/watch?v=etNb...
I've had the pleasure of knowing and meeting this lovely circle of utterly insane yet wonderful people. The past 12 months have been crazy, and it would have been less enjoyable without them.
Until next time...
www.youtube.com/watch?v=ETnB...
I've had the pleasure of knowing and meeting this lovely circle of utterly insane yet wonderful people. The past 12 months have been crazy, and it would have been less enjoyable without them.
Until next time...
www.youtube.com/watch?v=ETnB...
https://www.stocktitan.net/news/ETNB/89bio-to-participate-in-the-7th-annual-evercore-health-co-nx-4si29lo7k7k9.html
https://www.stocktitan.net/news/ETNB/89bio-to-participate-in-the-7th-annual-evercore-health-co-nx-4si29lo7k7k9.html
www.biopharmcatalyst.com/news/2025/89...
www.biopharmcatalyst.com/news/2025/89...
$1351.HK: mandatory offer at HK$0.25
$AMV0.DE: spin-off from $CON.DE
$WAH.DE: strategic review
$QLINEA.ST: rights issue
$ETNB: acquisition by $RO.SW for $14.5+$6 CVR
$1351.HK: mandatory offer at HK$0.25
$AMV0.DE: spin-off from $CON.DE
$WAH.DE: strategic review
$QLINEA.ST: rights issue
$ETNB: acquisition by $RO.SW for $14.5+$6 CVR
https://fundspec.io
Build Sophisticated AI driven valuation and momentum models on the FundSpec App available on the AppStore or PlayStore!
https://fundspec.io
Build Sophisticated AI driven valuation and momentum models on the FundSpec App available on the AppStore or PlayStore!
finance.yahoo.com/news/madriga...
$AKRO $ETNB
finance.yahoo.com/news/madriga...
$AKRO $ETNB
Until next year.
www.youtube.com/watch?v=ETnB...
Until next year.
www.youtube.com/watch?v=ETnB...
Stock Premarket - Sep 18, 2025
See StockQuakes.substack.com
UP
↑ ETNB 89Bio, Inc. 86.4%
↑ APVO Aptevo Therapeutics Inc. 68.8%
↑ AQB Aquabounty Technologies In... 34.6%
↑ INTC Intel Corp 29.0%
↑ LASE Laser Photonics Corp 28.9%
↑ ATCH Atlasclear Holdings, Inc. 22.8%
Stock Premarket - Sep 18, 2025
See StockQuakes.substack.com
UP
↑ ETNB 89Bio, Inc. 86.4%
↑ APVO Aptevo Therapeutics Inc. 68.8%
↑ AQB Aquabounty Technologies In... 34.6%
↑ INTC Intel Corp 29.0%
↑ LASE Laser Photonics Corp 28.9%
↑ ATCH Atlasclear Holdings, Inc. 22.8%
www.youtube.com/watch?v=ETnb...
diataxis.fr
@projectjupyter.bsky.social
www.youtube.com/watch?v=ETnb...
diataxis.fr
@projectjupyter.bsky.social
Die 89bio-Aktie (ISIN US28252C1099) steht nach der jüngsten Unternehmensübernahme im Fokus, denn für jede ETNB-Aktie wurde ein fester Barbetrag von 14,50 US-Dollar sowie eine zusätzliche Aktie des neuen Unternehmens gewährt, wie aus einem…
Die 89bio-Aktie (ISIN US28252C1099) steht nach der jüngsten Unternehmensübernahme im Fokus, denn für jede ETNB-Aktie wurde ein fester Barbetrag von 14,50 US-Dollar sowie eine zusätzliche Aktie des neuen Unternehmens gewährt, wie aus einem…
https://qian.cx/posts/F4C56F18-4DFD-48AD-9275-E75C5E4C4B07
https://qian.cx/posts/F4C56F18-4DFD-48AD-9275-E75C5E4C4B07
¡8u ǝʇnƃ
˙ʌÜʇ ɯnz pun ʇʇɐʇsʞɹǝʍ ɹnz ssnɯ oʇnɐ
˙snɐɹ ɥüɹɟ uǝƃɹoɯ ssnɯ ɥɔı ,os
😁
¡8u ǝʇnƃ
˙ʌÜʇ ɯnz pun ʇʇɐʇsʞɹǝʍ ɹnz ssnɯ oʇnɐ
˙snɐɹ ɥüɹɟ uǝƃɹoɯ ssnɯ ɥɔı ,os
😁